Nexalin Technology, Inc. announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device, has been granted regulatory approval by the Sultanate of Oman?s Ministry of Health.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.06 USD | -7.83% | -22.06% | +161.86% |
10/05 | Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
25/04 | Nexalin Technology Regains Compliance With Nasdaq Listing Requirement | MT |
1st Jan change | Capi. | |
---|---|---|
+161.86% | 85.52L | |
+10.22% | 23TCr | |
+12.99% | 20TCr | |
+18.09% | 14TCr | |
+28.66% | 11TCr | |
+2.09% | 6.53TCr | |
+14.70% | 5.44TCr | |
+6.68% | 5.09TCr | |
+8.29% | 4.48TCr | |
+2.60% | 3.68TCr |
- Stock Market
- Equities
- NXL Stock
- News Nexalin Technology, Inc.
- Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device